We carried out maintenance treatments for patients with tyrosine kinase inhibitors such as sorafenib for FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutated AML and dasatinib for Philadelphia chromosome-positive ALL (Ph+ ALL). The gene discussed is FLT3; the disease is acute myeloid leukemia.